No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SGMO240517C1000
- 0.04
- -0.01-20.00%
15min DelayClose May 15 16:00 ET
0.04High0.04Low
0.04Open0.05Pre Close1 Volume2.96K Open Interest1.00Strike Price4.00Turnover843.49%IV79.28%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.04Time Value100Contract SizeAmericanOptions Type0.2574Delta0.9613Gamma14.50Leverage Ratio-0.0309Theta0.0000Rho3.73Eff Leverage0.0001Vega
Intraday
- 5D
- 1D
News
Critical Insights From Sangamo Therapeutics Analyst Ratings: What You Need To Know
In the preceding three months, 4 analysts have released ratings for Sangamo Therapeutics (NASDAQ:SGMO), presenting a wide array of perspectives from bullish to bearish.The following table encapsulates
Express News | HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $5 Price Target
Sangamo Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 776.73% HC Wainwright & Co. → $5 Reiterates Buy → Buy 03/19/2024 776.73% HC Wainwright & Co. $3
US$3.50 - That's What Analysts Think Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Is Worth After These Results
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Sangamo Therapeutics Reports Q1 2024 Results: A Deep Dive Into Financials and Strategic Highlights
Comments
The MINT platform, derived from Sangamo's extensive experience in protein-DNA interactions through its zinc finger technology.
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
Sangamo Therapeutics recently presented critical pre-clinical data on its innovative next-generation integrase technology, the Modular Integrase (MINT) platform, highlighting a significant advancement in the field of genome editing. The announcement came as part of their participation at the 27th Amer...
$Sangamo Therapeutics(SGMO.US$ Sangamo Therapeutics To Present Neurology-Focused Pre-Clinical Data From Epigenetic Regulation, Capsid Delivery And Genome Engineering Platforms At 27th ASGCT Annual Meeting
1
1
2
The market anticipates continued poor revenue growth, potentially suppressing the P/S ratio. The company's forecast of declining revenue contributes to its low P/S. Without major changes, a drastic stock price increase seems unlikely.
2
$Sangamo Therapeutics(SGMO.US$ Sangamo Therapeutics Announces Data From STAC-BBB Demonstrating 'Robust Penetration of the Blood-brain Barrier (BBB) and Strong Transgene Expression Throughout the Central Nervous System (CNS) of NHPs'
Read more